Additional assumptions made within the Company’s 2020 guidance are as follows: Reconciliations of net income, the GAAP financial measure most directly comparable to Adjusted EBITDA and Non-GAAP net income, identifying the differences between each of these Non-GAAP financial measures and the most directly comparable GAAP financial measure, are included in this press release after the consolidated financial statements. The Investor Relations website contains information about Inovalon's business for stockholders, potential investors, and financial analysts. Reconciliations of net income to Adjusted EBITDA and Non-GAAP net income and reconciliations of net cash provided by operating activities to free cash flow identifying the differences between net income and net cash provided by operating activities and each of these Non-GAAP financial measures, are included in this press release after the consolidated financial statements. The words “believe,” “may,” “see,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “intend,” “expect,” “project,” “look forward,” “promise,” and similar expressions are intended to identify forward-looking statements. Investor Relations Global Contacts Inovalon Holdings Inc INOV Morningstar Rating Rating as of Dec 11, 2020. A replay of the event as well as a copy of presentation materials will be available on the website following the event. (3) Patient Analytics Months, or PAM, is defined as the sum of the analytical processes performed on each respective patient within patient populations covered by clients under contract. The Company is under no duty to, and disclaims any obligation to, update any of these forward-looking statements after the date of this press release or conform these statements to actual results or revised expectations, except as required by law. About Inovalon . All statements contained in this press release other than statements of historical fact, including but not limited to statements regarding the roll-out of any product or capability, the timing, performance characteristics and utility of any such product or capability, and the impact of any such product or capability on the healthcare industry, future results of operations and financial position, business strategy and plans, market growth, and objectives for future operations, are forward-looking statements. A replay of the event, as well as a copy of presentation materials, will be available on the website following the event. (2) Medical event count is defined as the total number of discrete medical events as of the end of the period presented (for example, a discrete medical event typically results from the presentation of a patient to a physician for the diagnosis of diabetes and congestive heart failure in a single visit, the presentation of a patient to an emergency department for chest pain, etc.). Ingredion … Net income is the GAAP financial measure most directly comparable to Adjusted EBITDA and Non-GAAP net income. Contact: Kim E. Collins Senior Vice President, Corporate Communications kcollins@inovalon.com 301-809-4000 x1473. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. However, use of free cash flow has limitations, and investors and others should not consider this measure in isolation or as a substitute for analysis of the Company’s liquidity as reported under GAAP. BOWIE, Md. Net loss per share attributable to common stockholders, basic and diluted: Weighted average shares of common stock outstanding: Includes stock-based compensation expense as follows: Accounts receivable (net of allowances of, Prepaid expenses and other current assets, Property, equipment and capitalized software, net, Operating lease liabilities, less current portion, Finance lease liabilities, less current portion, Total liabilities and stockholders’ equity. While changes in the stock price could change the fully diluted share count, under the treasury stock method, 2020 guidance assumes 150 million weighted average diluted shares. Investors frequently have requested information from management regarding depreciation, amortization and other non-cash charges, such as stock-based compensation, as well as the impact of non-comparable items and management believes, based on discussions with investors, that these non-GAAP measures enhance investors’ ability to assess Inovalon’s historical and projected future financial performance. Change. Each proprietary technology toolset, referred to as a Module, is informed by the data of billions of medical events within Inovalon’s proprietary datasets. Adjusted EBITDA, Adjusted EBITDA margin, Non-GAAP net income, and free cash flow are Non-GAAP measures. The Company defines Non-GAAP basic net income per share as Non-GAAP net income divided by basic weighted average shares outstanding. In addition, other companies, including companies in Inovalon’s industry, might calculate free cash flow or similarly titled measures differently, which may reduce their usefulness as comparative measures. For more information, visit www.inovalon.com. 12/01/20 Ingredion to Present at BMO 2020 Growth & ESG Conference. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. Good afternoon. Please see the Company’s filings with the Securities and Exchange Commission (“SEC”) for further detail regarding the preceding other financial data and key metrics. Inovalon Holdings, Inc.Consolidated Statements of Operations, _______________________________________________________, Inovalon Holdings, Inc.Consolidated Balance Sheets, Inovalon Holdings, Inc.Consolidated Statements of Cash Flows, Inovalon Holdings, Inc.Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization. Additional information is also set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020, included under Part I, Item 1A, “Risk Factors,” in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2020, filed with the SEC on April 29, 2020, including under Part II, Item IA, “Risk Factors,” and in subsequent filings with the SEC. Adjusted EBITDA margin is the Company’s calculation of Adjusted EBITDA, divided by revenue calculated in accordance with GAAP. Non-comparable items are excluded from Adjusted EBITDA in order to more effectively assess the Company’s period-over-period and ongoing operating performance.